Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture and sale of a range of products in the health care field worldwide. The company’s primary focus is products related to human health and well-being. The business of the company is conducted by approximately 250 operating companies located in 60 countries, including the U.S. Segments The company’s segments include Consumer, Pharmaceutical and Medical Devices. Consumer The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets. Baby Care includes the JOHNSON’S line of products. Oral Care includes the LISTERINE product line. Major brands in Skin Care include the AVEENO; CLEAN & CLEAR; DABAO; JOHNSON’S Adult; LE PETITE MARSEILLAIS; LUBRIDERM; NEUTROGENA; and RoC product lines. Over-the-counter medicines include the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; and the PEPCID line of heartburn products. Major brands in Women’s Health outside of North America are STAYFREE and CAREFREE sanitary pads and o.b. tampon brands. Wound Care brands include the BAND-AID Brand Adhesive Bandages and NEOSPORIN First Aid product lines. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. Pharmaceutical The Pharmaceutical segment is focused on five therapeutic areas: immunology (rheumatoid arthritis, inflammatory bowel disease, and psoriasis), infectious diseases and vaccines (HIV, hepatitis, respiratory infections, and tuberculosis), neuroscience (Alzheimer's disease, mood disorders, and schizophrenia), oncology (prostate cancer, hematologic malignancies, and lung cancer), and cardiovascular and metabolic diseases (thrombosis and diabetes). Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis; STELARA (ustekinumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis, and for adolescents with moderate to severe psoriasis; OLYSIO/SOVRIAD(simeprevir), for combination treatment of chronic hepatitis C in adult patients; PREZISTA (darunavir), EDURANT (rilpivirine), and PREZCOBIX/REZOLSTA (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral products; SIRTURO (bedaquiline), a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults (>
johnson & johnson
(JNJ:New York Consolidated)
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for JNJ.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact JOHNSON & JOHNSON, please visit www.jnj.com. Company data is provided by Capital IQ. Please use this form to report any data issues.